Skip to Main content Skip to Navigation
Journal articles

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

Aurelien Amiot 1, * Jerome Filippi 2 Vered Abitbol 3 Guillaume Cadiot 4 David Laharie 5 Melanie Serrero 6 Romain Altwegg 7 Yoram Bouhnik 8 Laurent Peyrin-Biroulet 9 Cyrielle Gilletta 10 Xavier Roblin 11 Guillaume Pineton de Chambrun 12, 13 Lucine Vuitton Anne Bourrier 14 Stephane Nancey 15 Jean-Marc Gornet 16 Stephane Nahon 17 Guillaume Bouguen 18, 19, 20 Stephanie Viennot 21 Benjamin Pariente 22 Mathurin Fumery 23
* Corresponding author
1 CHU Henri Mondor
2 CHU Nice - Centre Hospitalier Universitaire de Nice
3 AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris]
4 CHU Reims - Centre Hospitalier Universitaire de Reims
5 IBCP - Institut de biologie et chimie des protéines [Lyon]
6 Hôpital Nord [CHU - APHM]
7 CHU Saint-Eloi
8 Hôpital Beaujon [AP-HP]
9 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
10 CHU Toulouse [Toulouse]
11 GIMAP - Groupe Immunité des Muqueuses et Agents Pathogènes
12 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
13 Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB)
14 CR Saint-Antoine - Centre de Recherche Saint-Antoine
15 APY - Autophagie infection et immunité - Autophagy Infection Immunity
CIRI - Centre International de Recherche en Infectiologie - UMR
16 AP-HP - Hopital Saint-Louis [AP-HP]
17 Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
18 CHU Pontchaillou [Rennes]
19 NuMeCan - Nutrition, Métabolismes et Cancer
20 CIC - Centre d'Investigation Clinique [Rennes]
21 Hôpital Côte de Nacre [CHU Caen]
22 Hôpital Claude Huriez [Lille]
23 CHU Amiens-Picardie
Abstract : Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but few real-world data are currently available. Aim To assess short-term effectiveness and safety of ustekinumab in patients with UC. Methods From January to September 2019, all patients with UC treated with ustekinumab in 20 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (partial Mayo Clinic score <= 2) at weeks 12-16 without a rectal bleeding subscore >1. Results Among the 103 patients included, 70% had been previously exposed to >= 2 anti-TNF agents and 85% to vedolizumab. At weeks 12-16, steroid-free clinical remission and clinical remission rates were 35.0% and 39.8% respectively; the absence of rectal bleeding with normal stool frequency was noted in 19.4% of patients. Two patients discontinued ustekinumab before the week 12-16 visit and underwent surgery. In multivariable analysis, a partial Mayo Clinic score >6 at inclusion (18.6% vs 46.7%, P = 0.003) and a history of both exposure to anti-TNF and vedolizumab therapies (27.3% vs 80.0%, P = 0.001) were negatively associated with steroid-free clinical remission at weeks 12-16. Adverse events occurred in 7.8% of patients and serious adverse events in 3.9% of patients. Conclusion In a cohort of highly refractory patients with UC with multiple prior drug failures, ustekinumab provided steroid-free clinical remission in one-third of cases at weeks 12-16. Clinical severity and previous use of anti-TNF and vedolizumab therapies were associated with ustekinumab failure at weeks 12-16.
Keywords : Inflammatory bowel disease < Disease-based Ulcerative colitis Large intestine < Organ-based Immunosuppression < Topics Alimentary Pharmacology & Therapeutic
Document type :
Journal articles
Complete list of metadata

Cited literature [24 references]  Display  Hide  Download
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02798010
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Friday, July 17, 2020 - 2:42:28 PM
Last modification on : Monday, October 11, 2021 - 1:24:29 PM
Long-term archiving on: : Tuesday, December 1, 2020 - 12:16:28 AM

File

Vignette du document
effectiveness and safety of us...
Files produced by the author(s)

Identifiers

Collections

NUMECAN-EXPRES | UR1-UFR-SVE | UDL | BS | UNIV-MONTPELLIER | UNIV-RENNES | CIRI | SORBONNE-UNIVERSITE | NUMECAN | COMUE-NORMANDIE | UNIV-ST-ETIENNE | ENS-LYON | UNIV-RENNES1 | CNRS | UNIV-LYON1 | U938 | CIC | CIC203 | BIOSIT | SU-MEDECINE | INSERM | SU-TI | CIRI-M-FAURE-APY | CIRI-S-PAUL-GIMAP | UNIV-LORRAINE

Citation

Aurelien Amiot, Jerome Filippi, Vered Abitbol, Guillaume Cadiot, David Laharie, et al.. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Alimentary Pharmacology and Therapeutics, Wiley, 2020, 51 (11), pp.1039-1046. ⟨10.1111/apt.15717⟩. ⟨hal-02798010⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

889

Files downloads

1234